Invivyd Email Format

Biotechnology ResearchConnecticut, United States51-200 Employees

Invivyd is a biotechnology company based in New Haven, Connecticut, focused on developing antibody-based medicines designed to be highly potent and more resilient to viral evolution than the human immune system. The company uses a proprietary, integrated technology platform to guide the discovery, development, monitoring, and adaptation of antibodies, aiming to deliver preventive therapies with strong protective potential. Operating as a mid-sized organization, it concentrates on monoclonal antibodies within the biotechnology research sector.

Its work centers on preventing COVID-19 with antibody therapies, offering a vaccine-alternative option and exploring co-administration with vaccines in clinical trials. In June 2026, the company announced that the LIBERTY Phase 3 trial began dosing participants to evaluate the antibody alone, the vaccine alone, and their combination.

Sign up for free to view info

Company overview Employee directory